CVS forecast an adjusted profit of $1.14- $1.17 per share for the first quarter, below the average analyst estimate of $1.18, according to Thomson Reuters I/B/E/S. The net income attributable to the company rose 13.4 percent to $1.50 billion, or $1.34 per share, in the fourth quarter ended Dec. 31, helped by strong demand in its pharmacy business.» Read More
A new plan for Express Scripts regarding cancer drugs, with CNBC's Meg Tirrell.
BT Slingsby, CEO of the Global Health Innovative Technology Fund (GHIT), explains why it is developing new innovative health technologies to combat diseases like tuberculosis and malaria.
The American Society of Clinical Oncology conference will occur at the end of May in Chicago. CNBC's Meg Tirrell reports which companies investors should watch. Also, Les Funtleyder, ESquared Asset Management, shares his view.
A new report says the number of Americans being billed more than $100,000 a year for their prescriptions has tripled in the past year. CNBC's Meg Tirrell breaks down the report, saying slightly more than half of the spenders were men.
Music icon Willie Nelson is going into the weed business, according to a pot activist.
Mike Narachi, Orexigen CEO, speaks with CNBC's Meg Tirrell about its obesity drug and program.
Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.
CNBC's Jane Wells shares her top three predictions for the pot industry this year, including changing bank regulations and the beginning of voters' remorse where it's legal.
U.S. drugstore chain operator Walgreen reported a 16 percent rise in quarterly profit, helped by a record number of prescriptions filled.
Mark Fisher, MBF Clearing Corp. chairman, shares his favorite stock in the biotech space.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
Express Scripts Medical Chief Steve Miller, provides insight to his company's deal with AbbVie. The two companies have come to a deal which gives Express Scripts a significant discount on the hepatitis C drug.
CNBC's Meg Tirrell provides insight to a newly approved hepatitis C drug from AbbVie, which Express Scripts made an exclusive deal for a significant discount on the drug.
Intercept Pharmaceuticals CEO Mark Pruzanski, provides insight to his company's efforts to tackle NASH, or nonalcoholic steatohepatitis, saying over 10 percent of the U.S. population is thought to have NASH. Pruzanski also weighs in on being a public company.
Discussing warning signs from Dendreon, and other worrisome companies, with Les Funtleyder, E Square Asset Management.
Joseph Pantginis, Roth Capital, has been negative on Dendreon for a long time, ahead of the drugmaker's bankruptcy protection filing.
Kroger has delivered 43 straight quarters of rising sales at stores open at least a year.
Drug companies may be looking for legal protection amid a massive demand for Ebola vaccines, reports CNBC's Meg Tirrell.
Walgreen's former CFO sued the drugstore operator, alleging executives defamed him in news reports that blamed him for errors in its forecast.
GW Pharma shares are down sharply after a study of its treatment for ulcerative colitis missed its primary endpoint in a mid-stage trial. GW Pharmaceuticals CEO Justin Gover, says the company's main focus is on its product for epilepsy.